A nurse educates parents about non-stimulant medications used to treat attention-deficit/hyperactivity disorder (ADHD). Which medication is a non-stimulant option?
Atomoxetine (Strattera).
Methylphenidate (Ritalin).
Dextroamphetamine (Dexedrine).
Lisdexamfetamine (Vyvanse).
The Correct Answer is A
Non-stimulant therapy for ADHD includes atomoxetine, a selective norepinephrine reuptake inhibitor. Unlike stimulants, it does not directly increase dopamine release but modulates norepinephrine transmission, improving attention and impulse control. Atomoxetine is useful in patients with contraindications to stimulants, comorbid anxiety, or risk of substance misuse.
Rationale for correct answer:
1. Atomoxetine (Strattera) is a non-stimulant norepinephrine reuptake inhibitor approved for ADHD. It improves attentional control without the abuse potential of stimulants. It is particularly beneficial in children with comorbid anxiety or those intolerant to stimulant side effects.
Rationale for incorrect answers:
2. Methylphenidate (Ritalin) is a stimulant that blocks dopamine and norepinephrine reuptake. It is first-line therapy for ADHD but not classified as non-stimulant.
3. Dextroamphetamine (Dexedrine) is a stimulant that increases dopamine and norepinephrine release. It is effective for ADHD but carries abuse potential, making it unsuitable as a non-stimulant option.
4. Lisdexamfetamine (Vyvanse) is a stimulant prodrug of dextroamphetamine. It is long-acting and effective for ADHD but remains a stimulant, not a non-stimulant medication.
Test-taking strategy
- Identify the main concept: non-stimulant ADHD medication.
- Recall that stimulants (methylphenidate, amphetamines) are first-line but not non-stimulant.
- Rule out distractors:
- Methylphenidate = stimulant.
- Dextroamphetamine = stimulant.
- Lisdexamfetamine = stimulant.
- Focus on the option that is FDA-approved as a non-stimulant.
- Correct answer emerges by matching atomoxetine to non-stimulant pharmacology.
Take home points
- Atomoxetine is the primary non-stimulant approved for ADHD.
- Stimulants include methylphenidate, dextroamphetamine, and lisdexamfetamine.
- Atomoxetine is preferred in patients with anxiety or substance misuse risk.
- Differentiating stimulant from non-stimulant therapy is essential in ADHD management.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is C
Explanation
Dextroamphetamine is a stimulantthat enhances dopamineand norepinephrineactivity, improving attention and impulse control in ADHD. However, it frequently causes anorexiaand weight loss due to appetite suppression. Administering the drug after meals helps reduce nutritional impact by allowing adequate intake before appetite suppression begins.
Rationale for correct answer:
3.Administering dextroamphetamine after meals minimizesanorexiaby ensuring the child eats before appetite suppression occurs. This intervention directly addresses imbalanced nutrition and supports growth and weight maintenance in pediatric ADHD clients.
Rationale for incorrect answers:
1.Monitoring output and sleep patterns daily is important for stimulant therapy but does not directly addressnutrition. It helps detect insomnia or urinary changes, yet it fails to correct anorexia-related weight loss.
2.Administering medication with food prevents nausea, not anorexia. Stimulants primarily suppress appetite rather than cause gastrointestinal upset. This intervention does not resolve the nutritional deficit associated with dextroamphetamine.
4.Increasing fiber and fluid intake prevents constipation, a possible side effect of stimulants. While beneficial, it does not address anorexia or weight loss, which are the primary nutritional concerns in this scenario.
Test-taking strategy
- Identify the main issue: imbalanced nutrition due to anorexia from stimulant therapy.
- Recall stimulant side effects: appetite suppression, insomnia, headache, abdominal pain.
- Rule out distractors:
- Monitoring sleep/output = general care, not nutrition.
- With food = prevents nausea, not anorexia.
- Fiber/fluid = prevents constipation, not anorexia.
- Focus on the intervention that directly improves nutritional intake.
- Correct answer emerges by matching anorexia management with timing of medication administration.
Take home points
- Stimulants like dextroamphetamine suppress appetite, leading to anorexia and weight loss.
- Administering medication after meals helps preserve nutritional intake.
- Other interventions address side effects but not anorexia.
- Nurses must monitor growth and weight in children on stimulant therapy.
Correct Answer is ["B","D","E","F"]
Explanation
Methylphenidate is a stimulantmedication that enhances dopamineand norepinephrineactivity in the prefrontal cortex, improving attention and impulse control. Common adverse effects include insomnia, decreased appetite, headache, abdominal pain, and potential risk of seizures. Cardiovascular effects usually involve mild hypertension or tachycardia, not hypotension.
Rationale for correct answers:
2.Decreased appetite is a frequent side effect due to stimulant-induced suppression ofdopaminergicpathwaysregulating hunger. This can lead to weight loss in children, requiring monitoring of growth and nutritional intake.
4.Insomnia occurs because stimulantsincrease CNS activity. Evening dosing exacerbates sleep disturbance. Nurses should advise morning administration and monitor sleep hygiene to reduce impact on rest.
5.Headache is a common adverse effect linked to stimulant-induced changes inneurotransmitterbalance. It is usually mild but can interfere with adherence, requiring symptomatic management.
6.Seizures are a rare but serious adverse effect. Stimulants lower the seizure threshold, especially in clients with preexisting epilepsy. Monitoring neurological status is essential to detect early warning signs.
Rationale for incorrect answers:
1.Hypotension is not typical of methylphenidate. Stimulants usually cause hypertension or tachycardia due to sympathetic activation. Monitoring blood pressure is important, but hypotension is not expected.
3.Sedation is inconsistent with stimulant pharmacology. Methylphenidate increases alertness and activity, not drowsiness. Sedationwould suggest another drug effector comorbidity, not methylphenidate.
Test-taking strategy
- Identify the main drug: methylphenidate, a stimulant.
- Recall stimulant side effects: insomnia, appetite suppression, headache, abdominal pain, possible seizures.
- Rule out distractors:
- Hypotension is not expected; stimulants raise blood pressure.
- Sedation contradicts stimulant pharmacology.
- Focus on adverse effects consistent with CNS stimulationand appetite suppression.
- Use elimination methodology: remove options inconsistent with stimulant effects.
- Correct answers emerge by matching stimulant pharmacodynamics to expected clinical manifestations.
Take home points
- Methylphenidate commonly causes decreased appetite, insomnia, and headache.
- Seizures are rare but serious adverse effects requiring monitoring.
- Hypotension and sedation are not expected with stimulant therapy.
- Nurses must monitor growth, sleep, and neurological status in children on methylphenidate.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.
